Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 3906-3913

  Uckun, Fatih M ^a,g   Messinger, Yoav ^b   Chen, Chun Lin ^a   O'Neill, Karen ^a   Myers, Dorothea E ^a   Goldman, Frederick ^d   Hurvitz, Carole ^e   Casper, James T ^f   Levine, Alexandra ^c  

^a Parker Hughes Cancer Center   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^g PARKER HUGHES INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; GENISTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CAPILLARY LEAK SYNDROME; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; FEVER; HUMAN; MALE; MYALGIA; PRIORITY JOURNAL; SINUS TACHYCARDIA;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS; APOPTOSIS; CHILD; CHILD, PRESCHOOL; ENZYME INHIBITORS; FEMALE; GENISTEIN; HUMANS; IMMUNOTOXINS; LEUKEMIA, B-CELL, ACUTE; MALE; MIDDLE AGED; PILOT PROJECTS; PROTEIN-TYROSINE KINASES;

EID: 0033387144     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Uckun, F. M., Burkhardt, A. L., Jarvis, L., Jun, X., Stealey, B., Dibirdik, I., Myers, D. E., Tuel Ahlgren, L., and Bolen, J. B. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J. Biol. Chem., 268: 21172-21184, 1993.
2. Uckun, F. M., Jaszcz, W., Ambrus, J. L., Fauci, A. S., Gajl-Peczalska, K., Song, C. W., Wick, M. R., Myers, D. E., Waddick, K., and Ledbetter, J. A. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti- CD19 immunotoxins. Blood, 71: 13-29, 1988.
3. Uckun, F. M., Gajl-Peczalska, K. J., Kersey, J. H., Houston, L. L., and Vallera, D. A. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. J. Exp. Med., 163: 347-368, 1986.
4. Uckun, F. M. Regulation of human B-cell ontogeny (Review). Blood, 76: 1908-1923, 1990.
5. + acute lymphoblastic leukemia: a Children's Cancer Group study. Blood, 89: 2488-2493, 1997.
6. Uckun, F. M., Sather, H., Gaynon, P., Arthur, D., Trigg, M., Tubergen, D., Nachman, J., Steinherz, P., Sensel, M., and Reaman, G. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood, 90: 28-35, 1997.
7. Uckun, F. M., Sensel, M. G., Sather, H. N., Gaynon, P. S., Arthur, D. C., Lange, B. J., Steinherz, P. G., Kraft, P., Hutchinson, R., Nachman, J. B., Reaman, G. H., and Heerema, N. A. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J. Clin. Oncol., 16: 527-535, 1998.
8. Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick, K. G., Ahlgren, L. T., Chelstrom, L. M., Burkhardt, A., Bolen, J., and Myers, D. E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science (Washington DC), 267: 886-891, 1995.
9. Myers, D. E., Jun, X., Waddick, K. G., Forsyth, C., Chelstrom, L. M., Gunther, R. L., Tumer, N. E., Bolen, J., and Uckun, F. M. Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells (published erratum appears in Proc. Natl. Acad. Sci. USA 1996 Feb. 6; 93:1357). Proc. Natl. Acad. Sci. USA, 92: 9575-9579, 1995.
10. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., and Fukami, Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 262: 5592-5595, 1987.
11. Ek, O., Yanishevski, Y., Zeren, T., Waurzyniak, B., Gunther, R., Chelstrom, L., Chandan-Langlie, M., Schneider, E., Myers, D. E., Evans, W., and Uckun, F. M. In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-genistein immunoconjugate. Leuk. Lymphoma, 30: 389-394, 1998.
12. Messinger, Y., Yanishevski, Y., Ek, O., Zeren, T., Waurzyniak, B., Gunther, R., Chelstrom, L., Chandan-Langlie, M., Schneider, E., Myers, D. E., Evans, W., and Uckun, F. M. In vivo toxicity and pharmacokinetic features of B43(anti-CD19)-genistein immunoconjugate in non-human primates. Clin. Cancer Res., 4: 165-170, 1998.
13. Myers, D. E., Sicheneder, A., Clementson, D., Dvorak, N., Venkatachalam, T., Rostovsev, A., Chandan-Langlie, M., and Uckun, F. M. Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma. Leuk. Lymphoma, 29: 329-338, 1998.
14. Chen, C. L., Malaviya, R., Navara, C., Chen, H., Bechard, B., Mitcheltree, G., Liu, X. P., and Uckun, F. M. Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3-hydroxphenyl)-amino-6,7-dimethoxyquinazoline in mice. Pharm. Res., 16: 117-122, 1999.
15. Uckun, F. M., Yanishevski, Y., Tumer, N., Waurzyniak, B., Messinger, Y., Chelstrom, L. M., Lisowski, E. A., Ek, O., Zeren, T., Wendorf, H., Langlie, M. C., Irvin, J. D., Myers, D. E., Fuller, G. B., Evans, W., and Gunther, R. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti- CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys. Clin. Cancer Res., 3: 325-337, 1997.
16. Mcleod, H. L., Brunton, V. G., Eckardt, N., Lear, M. J., Robins, D. J., Workman, P., and Graham, M. A. In vivo pharmacology and anti-tumor evaluation of the tryphostin tyrosine kinase inhibitor RG13022. Br. J. Cancer, 74: 1714-1718, 1996.
17. Ferry, D. R., Smith, A., Malkhandi, J., Fyfe, D. W., deTakats, P. G., Anderson, D., Baker, J., and Kerr, D. J. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res., 2: 659-668, 1996.